Neural stem cell therapies for spinal cord injury repair: an update on recent preclinical and clinical advances
Brain · 01.03.2024 · 147 (3) · 766-793
DOI: 10.1093/brain/awad392 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain, online erschienen am 17.11.2023. Verfasst von Seyed Mojtaba Hosseini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pathophysiology, Spinal Cord Research Centre, Rady Faculty of Health Sciences, University of Manitoba Winnipeg, Manitoba…. Hauptthemen laut MEDLINE: Neural Stem Cells, Spinal Cord Injuries. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 339 Literaturangaben. Gefördert von: Canadian Institute of Health Research, Wings for Life, University of Manitoba Graduate Fellowship, Will-to-Win/Manitoba Paraplegic Foundation.
Abstract (Originalsprache)
Traumatic spinal cord injury (SCI) is a leading cause of lifelong disabilities. Permanent sensory, motor and autonomic impairments after SCI are substantially attributed to degeneration of spinal cord neurons and axons, and disintegration of neural network. To date, minimal regenerative treatments are available for SCI with an unmet need for new therapies to reconstruct the damaged spinal cord neuron-glia network and restore connectivity with the supraspinal pathways. Multipotent neural precursor cells (NPCs) have a unique capacity to generate neurons, oligodendrocytes and astrocytes. Due to this capacity, NPCs have been an attractive cell source for cellular therapies for SCI. Transplantation of NPCs has been extensively tested in preclinical models of SCI in the past two decades. These studies have identified opportunities and challenges associated with NPC therapies. While NPCs have the potential to promote neuroregeneration through various mechanisms, their low long-term survival and integration within the host injured spinal cord limit the functional benefits of NPC-based therapies for SCI. To address this challenge, combinatorial strategies have been developed to optimize the outcomes of NPC therapies by enriching SCI microenvironment through biomaterials, genetic and pharmacological therapies. In this review, we will provide an in-depth discussion on recent advances in preclinical NPC-based therapies for SCI. We will discuss modes of actions and mechanism by which engrafted NPCs contribute to the repair process and functional recovery. We will also provide an update on current clinical trials and new technologies that have facilitated preparation of medical-grade human NPCs suitable for transplantation in clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology and Pathophysiology, Spinal Cord Research Centre, Rady Faculty of Health Sciences, University of Manitoba Winnipeg, Manitoba R3E 0J9, Canada.
- Manitoba Multiple Sclerosis Research Center, Winnipeg, Manitoba R3E 0J9, Canada.
- Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba R3E 3P4, Canada.
ORCID-Profile: Soheila Karimi-Abdolrezaee
Förderung
- Canadian Institute of Health Research
- Wings for Life, University of Manitoba Graduate Fellowship
- Will-to-Win/Manitoba Paraplegic Foundation
- Medical Student Research Program
- University of Manitoba
Zitieren
APA
Hosseini, S. M., Borys, B., & Karimi-Abdolrezaee, S. (2024). Neural stem cell therapies for spinal cord injury repair: an update on recent preclinical and clinical advances. Brain, 147(3), 766-793. https://doi.org/10.1093/brain/awad392
Vancouver
Hosseini SM, Borys B, Karimi-Abdolrezaee S. Neural stem cell therapies for spinal cord injury repair: an update on recent preclinical and clinical advances. Brain. 2024;147(3):766-793. doi:10.1093/brain/awad392
BibTeX
@article{Hosseini2024,
author = {Hosseini, Seyed Mojtaba and Borys, Ben and Karimi-Abdolrezaee, Soheila},
title = {Neural stem cell therapies for spinal cord injury repair: an update on recent preclinical and clinical advances},
journal = {Brain},
year = {2024},
volume = {147},
number = {3},
pages = {766--793},
doi = {10.1093/brain/awad392}
}
EUVIMED